论文部分内容阅读
目的 :比较皮质类固醇激素和非甾体激素对预防PRK术后角膜混浊的疗效。方法 :双眼屈光相同的近视患者 50人 ( 1 0 0只眼 )、分为 2组 ,第一组屈光度为 >3 0D ,≤ 6 0D ,3 2人 ( 64只眼 ) ;第二组屈光度为 >6 0D、≤ 1 2 0D ,1 8人 ( 3 6只眼 )。PRK术后按美国FDA标准主观评定角膜混浊。所有患者右眼使用 0 1 %艾氟龙预防角膜混浊 ,左眼使用 0 0 3 %欧可芬预防角膜混浊。结果 :第一组 3个月双眼角膜混浊均消退 ,角膜透明。第二组 6个月后 0 1 %艾氟龙治疗眼有 4只眼残存角膜混浊 ,0 0 3 %欧可芬治疗眼有 8只眼残存角膜混浊。结论 :低、中度近视PRK术后 0 1 %艾氟龙与 0 0 3 %欧可芬效果相同 ,且非甾体激素治疗眼无眼压升高 ,在低、中度近视可应用 0 0 3 %欧可芬预防角膜混浊。在高度近视眼 0 1 %艾氟龙优于 0 0 3 %欧可芬
Objective: To compare the efficacy of corticosteroids and non-steroidal hormones in preventing corneal opacity after PRK surgery. Methods: 50 eyes (100 eyes) with the same myopic eyes were divided into two groups. The first group of diopters was> 300D, ≤60D, and 32 eyes (64 eyes). The second group of diopters > 6 0D, ≤ 120D, 18 (36 eyes). PRK subjective assessment of corneal opacity by the United States FDA standards. Corneal opacity was prevented with 0 1% of alloxan in the right eye and 0 0 3% of opulentine in the left eye in all patients. Results: The first group of 3 months binocular opacity were subsided, corneal transparency. The second group of 6 months after 0 1% etofenone treatment of 4 eyes residual corneal opacity, 0 0 3% ophthalmic treatment of 8 eyes residual corneal opacity. CONCLUSIONS: 0 1% of etofenan and 0 0 3% of Okofen in patients with low or moderate myopia have the same effect and no intraocular pressure is elevated in patients with non-steroidal hormones. In low and moderate myopia, 0 0 3% Okofen prevents corneal opacity. In high myopia 0 1% difluoride is better than 0 0 3% opulent